The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002
Abstract
Purpose: Few treatment options exist for adult T-cell leukemia/lymphoma (ATL), and the prognosis for this disease is poor. A phase I study of lenalidomide demonstrated preliminary antitumor activity in patients with relapsed ATL. The current phase II study evaluated the efficacy and safety of lenalidomide monotherapy in patients with relapsed or recurrent ATL. Patients and Methods: Patients 20 years of age or older with acute, lymphoma, or unfavorable chronic subtype ATL, who had received one or more prior anti-ATL systemic chemotherapy and achieved stable disease or better on their last anti-ATL therapy with subsequent relapse or recurrence, were eligible. Patients received oral lenalidomide 25 mg/d continuously until disease progression or unacceptable toxicity. The primary end point was overall response rate; secondary end points included safety, tumor control rate (stable disease or better), time to response, duration of response, time to progression, progression-free survival, and overall survival. Results: Objective responses were noted in 11 of 26 patients (overall response rate, 42%; 95% CI, 23% to 63%), including four complete responses and one unconfirmed complete response. The tumor control rate was 73%. The median time to response and duration of response were 1.9 months and not estimable, respectively, and the median time to progression was 3.8 months. The median progression-free survival and overall survival were 3.8 and 20.3 months, respectively. The most frequent grade ≥ 3 adverse events were neutropenia (65%), leukopenia (38%), lymphopenia (38%), and thrombocytopenia (23%), which were all manageable and reversible. Conclusion: Lenalidomide demonstrated clinically meaningful antitumor activity and an acceptable toxicity profile in patients with relapsed or recurrent aggressive ATL, hinting at its potential to become a treatment option. Further investigations of lenalidomide in ATL and other mature T-cell neoplasms are warranted.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is approved in Japan for the treatment of relapsed and refractory (R/R) ATL with improved ORR [209].”
From Current State of Therapeutics for HTLV-1 (2024) · cites this paper as [209]
In the citing paper
“In early phase studies, single-agent lenalidomide typically induced responses in ~30% (ORRs of 22–42%) of patients with R/R peripheral T cell lymphomas90–92, mycosis fungoides or Sézary syndrome93.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [93]
Citations
Cites
Poiesz, B. J., Ruscetti, F. W., Gazdar, A. F., Bunn, P. A., Minna, J. D., & Gallo, R. C. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.12.7415 · Cited by 5,043
Adult T-cell leukemia: clinical and hematologic features of 16 cases
Uchiyama, T., Yodoi, J., Sagawa, K., Takatsuki, K., & Uchino, H. (1977) · Blood · doi:10.1182/blood.v50.3.481.bloodjournal503481 · Cited by 2,315
Hinuma, Y., Nagata, K., Hanaoka, M., Nakai, M., Matsumoto, T., Kinoshita, K. I., Shirakawa, S., & Miyoshi, I. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.10.6476 · Cited by 2,252
Yoshida, M., Miyoshi, I., & Hinuma, Y. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.6.2031 · Cited by 2,169
International T-Cell Lymphoma Project (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.4558 · Cited by 2,124
Shimoyama, M., & members of The Lymphoma Study Group (1984–87) (1991) · British Journal of Haematology · doi:10.1111/j.1365-2141.1991.tb08051.x · Cited by 1,608
The evolution of thalidomide and its IMiD derivatives as anticancer agents
Bartlett, J. B., Dredge, K. S., & Dalgleish, A. G. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1323 · Cited by 817
Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814
Duvic, M., Hymes, K., Heald, P., Breneman, D., Martin, A. G., Myskowski, P., Crowley, C., Yocum, R. C., & for Members of the Bexarotene Worldwide Study Group (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2456 · Cited by 706
Ishida, T., Joh, T., Uike, N., Yamamoto, K., Utsunomiya, A., Yoshida, S., Saburi, Y., Miyamoto, T., Takemoto, S., Suzushima, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.3472 · Cited by 657
Self-citation
Cited by
Sorted by citations
Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report
Cook, L. B., Fuji, S., Hermine, O., Bazarbachi, A., Ramos, J. C., Ratner, L., Horwitz, S., Fields, P., Tanase, A., Bumbea, H., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00501 · Cited by 267
Self-citationIzutsu, K., Makita, S., Nosaka, K., Yoshimitsu, M., Utsunomiya, A., Kusumoto, S., Morishima, S., Tsukasaki, K., Kawamata, T., Ono, T., et al. (2023) · Blood · doi:10.1182/blood.2022016862 · Cited by 167
Self-citationPrognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma
Kataoka, K., Iwanaga, M., Yasunaga, J., Nagata, Y., Kitanaka, A., Kameda, T., Yoshimitsu, M., Shiraishi, Y., Sato‐Otsubo, A., Sanada, M., et al. (2017) · Blood · doi:10.1182/blood-2017-01-761874 · Cited by 161
Self-citationFutsch, N., Mahieux, R., & Dutartre, H. (2017) · Viruses · doi:10.3390/v10010001 · Cited by 155
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137
Adult T-Cell Leukemia/Lymphoma
Mehta–Shah, N., Ratner, L., & Horwitz, S. M. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2017.021907 · Cited by 93
Hermine, O., Ramos, J. C., & Tobinai, K. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0658-4 · Cited by 96
Self-citationKatsuya, H., Islam, S., Tan, B. J. Y., Ito, J., Miyazato, P., Matsuo, M., Inada, Y., Iwase, S. C., Uchiyama, Y., Hata, H., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.016 · Cited by 92
Self-citationHow I treat adult T-cell leukemia/lymphoma
Cook, L. B. M., & Phillips, A. A. (2020) · Blood · doi:10.1182/blood.2019004045 · Cited by 85
Nosaka, K., Iwanaga, M., Imaizumi, Y., Ishitsuka, K., Ishizawa, K., Ishida, Y., Amano, M., Ishida, T., Uike, N., Utsunomiya, A., et al. (2017) · Cancer Science · doi:10.1111/cas.13398 · Cited by 85
Self-citationClinical and Public Health Implications of Human T-Lymphotropic Virus Type 1 Infection
Legrand, N., McGregor, S., Bull, R. A., Bajis, S., Valencia, B. M., Ronnachit, A., Einsiedel, L. J., Gessain, A., Kaldor, J. M., & Martinello, M. (2022) · Clinical Microbiology Reviews · doi:10.1128/cmr.00078-21 · Cited by 87
Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma
Narita, T., Ishida, T., Ito, A., Masaki, A., Kinoshita, S., Suzuki, S., Takino, H., Yoshida, T., Ri, M., Kusumoto, S., et al. (2017) · Blood · doi:10.1182/blood-2016-09-741983 · Cited by 71
Self-citationIshida, T., Utsunomiya, A., Jo, T., Yamamoto, K., Kato, K., Yoshida, S., Takemoto, S., Suzushima, H., Kobayashi, Y., Imaizumi, Y., et al. (2017) · Cancer Science · doi:10.1111/cas.13343 · Cited by 71
Self-citationPhillips, A. A., Fields, P. A., Hermine, O., Ramos, J. C., Beltran, B. E., Pereira, J., Wandroo, F., Feldman, T., Taylor, G. P., Sawas, A., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.205096 · Cited by 70
Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma
Katsuya, H., Shimokawa, M., Ishitsuka, K., Kawai, K., Amano, M., Utsunomiya, A., Hino, R., Hanada, S., Jo, T., Tsukasaki, K., et al. (2017) · Blood · doi:10.1182/blood-2017-01-757542 · Cited by 66
Self-citationDiagnostic Approaches and Established Treatments for Adult T Cell Leukemia Lymphoma
Tsukasaki, K., Marçais, A., Nasr, R., Kato, K., Fukuda, T., Hermine, O., & Bazarbachi, A. A. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01207 · Cited by 62
Self-citationUtsunomiya, A., Izutsu, K., Jo, T., Yoshida, S., Tsukasaki, K., Ando, K., Choi, I., Imaizumi, Y., Kato, K., Kurosawa, M., et al. (2022) · Cancer Science · doi:10.1111/cas.15431 · Cited by 52
Self-citationNovel Treatments of Adult T Cell Leukemia Lymphoma
Hajj, H. E., Tsukasaki, K., Cheminant, M., Bazarbachi, A. A., Watanabe, T., & Hermine, O. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01062 · Cited by 52
Self-citationAdult T Cell Leukemia-Lymphoma (ATL): State of the Art
Phillips, A. A., & Harewood, J. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0458-6 · Cited by 46
The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL)
Ma, H., Davarifar, A., & Amengual, J. E. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0432-3 · Cited by 44
Davis, D. A., Shrestha, P., Aisabor, A. I., Stream, A., Galli, V., Pise-Masison, C. A., Tagawa, T., Ziegelbauer, J. M., Franchini, G., & Yarchoan, R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1546544 · Cited by 44
Biomarker-driven management strategies for peripheral T cell lymphoma
Mulvey, E. C., & Ruan, J. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00889-z · Cited by 43
Progress in Allogeneic Hematopoietic Cell Transplantation in Adult T-Cell Leukemia-Lymphoma
Utsunomiya, A. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02235 · Cited by 41
PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia/Lymphoma
Jalili‐Nik, M., Soltani, A., Mashkani, B., Rafatpanah, H., & Hashemy, S. I. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107870 · Cited by 41
Treatment advances and prognosis for patients with adult T-cell leukemia-lymphoma
Katsuya, H., & Ishitsuka, K. (2017) · Journal of the Japan Society of the Reticuloendothelial System · doi:10.3960/jslrt.17008 · Cited by 38
Mogamulizumab for adult T-cell leukemia-lymphoma: a multicenter prospective observational study
Yonekura, K., Kusumoto, S., Choi, I., Nakano, N., Ito, A., Suehiro, Y., Imaizumi, Y., Yoshimitsu, M., Nosaka, K., Ohtsuka, E., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020003053 · Cited by 38
Self-citationDevelopment of new agents for peripheral T-cell lymphoma
Ito, Y., Makita, S., & Tobinai, K. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1572746 · Cited by 37
Self-citationRuan, J., Zain, J. M., Palmer, B. A., Jovanovic, B. D., Mi, X., Swaroop, A., Winter, J. N., Gordon, L. I., Karmali, R., Moreira, J., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023009767 · Cited by 36
Mogamulizumab for the treatment of T-cell lymphoma
Makita, S., & Tobinai, K. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1347634 · Cited by 39
Self-citationHuman T-Lymphotropic Virus (HTLV): Epidemiology, Genetic, Pathogenesis, and Future Challenges
Branda, F., Romano, C., Pavia, G., Bilotta, V., Locci, C., Azzena, I., Deplano, I., Pascale, N., Perra, M. T., Giovanetti, M., et al. (2025) · Viruses · doi:10.3390/v17050664 · Cited by 37
Kannagi, M., Hasegawa, A., Nagano, Y., Iino, T., Okamura, J., & Suehiro, Y. (2019) · Cancer Science · doi:10.1111/cas.13948 · Cited by 33
Ito, A., Nakano, N., Tanaka, T., Fuji, S., Makiyama, J., Inoue, Y., Choi, I., Nakamae, H., Nagafuji, K., Takase, K., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004932 · Cited by 32
Miyoshi, H., & Ohshima, K. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2430-6 · Cited by 31
Nakahata, S., Enríquez, D., Jahan, M. I., Sugata, K., & Satou, Y. (2023) · Biomolecules · doi:10.3390/biom13101543 · Cited by 31
Yamshon, S., & Ruan, J. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00536-6 · Cited by 30
Makiyama, J., Kobayashi, S., Watanabe, E., Ishigaki, T., Kawamata, T., Nakashima, M., Yamagishi, M., Nakano, K., Tojo, A., Watanabe, T., et al. (2019) · Cancer Science · doi:10.1111/cas.14219 · Cited by 30
Mehta–Shah, N., Lunning, M. A., Moskowitz, A. J., Boruchov, A. M., Ruan, J., Lynch, P., Hamlin, P. A., Leonard, J. P., Matasar, M. J., Myskowski, P. L., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26288 · Cited by 29
Ikebe, E., Shimosaki, S., Hasegawa, H., Iha, H., Tsukamoto, Y., Wang, Y., Sasaki, D., Imaizumi, Y., Miyazaki, Y., Yanagihara, K., et al. (2021) · Cancer Science · doi:10.1111/cas.15204 · Cited by 29
Self-citationKato, K., Uike, N., Wake, A., Yoshimitsu, M., Tobai, T., Sawayama, Y., Takatsuka, Y., Fukuda, T., Uchida, N., Eto, T., et al. (2018) · Hematological Oncology · doi:10.1002/hon.2558 · Cited by 28
Self-citationClinical significance of TP53 mutations in adult T‐cell leukemia/lymphoma
Sakamoto, Y., Ishida, T., Masaki, A., Murase, T., Takeshita, M., Muto, R., Iwasaki, H., Ito, A., Kusumoto, S., Nakano, N., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17749 · Cited by 28
Self-citationSakamoto, H., Itonaga, H., Sawayama, Y., Furumoto, T., Fujioka, M., Chiwata, M., Toriyama, E., Kasai, S., Nakashima, J., Horai, M., et al. (2020) · Hematological Oncology · doi:10.1002/hon.2712 · Cited by 28
Self-citationAn activating mutation of interferon regulatory factor 4 (IRF4) in adult T-cell leukemia
Cherian, M. A., Olson, S. L., Sundaramoorthi, H., Cates, K. L., Cheng, X., Harding, J., Martens, A., Challen, G. A., Tyagi, M. G., Ratner, L., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000164 · Cited by 27
Adult T-Cell Leukemia: a Comprehensive Overview on Current and Promising Treatment Modalities
Hleihel, R., Akkouche, A., Skayneh, H., Hermine, O., Bazarbachi, A. A., & Hajj, H. E. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01138-3 · Cited by 24
Hajj, H. E., & Bazarbachi, A. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.957535 · Cited by 27
Hsu, A., Huntington, K. E., Souza, A. O., Zhou, L., Olszewski, A. J., Makwana, N., Treaba, D. O., Cavalcante, L. L., Giles, F. J., Safran, H. P., et al. (2022) · Cancer Biology & Therapy · doi:10.1080/15384047.2022.2088984 · Cited by 23
Current State of Therapeutics for HTLV-1
Wang, T. T., Hirons, A., Doerflinger, M., Morris, K. V., Ledger, S., Purcell, D. F. J., Kelleher, A. D., & Ahlenstiel, C. L. (2024) · Viruses · doi:10.3390/v16101616 · Cited by 22
“Treatments for HTLV-1-associated diseases and infection.”
Oh, Y., Stoll, J. R., Moskowitz, A. J., Pulitzer, M. P., Horwitz, S. M., Myskowski, P. L., & Noor, S. J. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.04.081 · Cited by 22
Sando, Y., Matsuoka, K., Sumii, Y., Kondo, T., Ikegawa, S., Sugiura, H., Nakamura, M., Iwamoto, M., Meguri, Y., Asada, N., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-74174-x · Cited by 22
Outlines of the Japanese guidelines for the management of primary cutaneous lymphomas 2020
Ohtsuka, M., Hamada, T., Miyagaki, T., Shimauchi, T., Yonekura, K., Kiyohara, E., Fujita, H., Izutsu, K., Okuma, K., Kawai, K., et al. (2020) · The Journal of Dermatology · doi:10.1111/1346-8138.15707 · Cited by 21
Oncoviruses: How do they hijack their host and current treatment regimes
Ahmed, K., & Jha, S. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188960 · Cited by 19
Clinical significance of CD28 gene‐related activating alterations in adult T‐cell leukaemia/lymphoma
Sakamoto, Y., Ishida, T., Masaki, A., Takeshita, M., Iwasaki, H., Yonekura, K., Tashiro, Y., Ito, A., Kusumoto, S., Utsunomiya, A., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.17211 · Cited by 19
Self-citationCurrent and emerging therapeutic strategies in adult T-cell leukemia–lymphoma
Katsuya, H. (2023) · International Journal of Hematology · doi:10.1007/s12185-023-03572-4 · Cited by 18
Kawamura, K., Tanaka, Y., Nakasone, H., Ishihara, Y., Kako, S., Kobayashi, S., Tanaka, Y., Ohmori, T., Uchimaru, K., Okamoto, S., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.04.006 · Cited by 19
Tanaka, T., Inamoto, Y., Ito, A., Watanabe, M., Takeda, W., Aoki, J., Kim, S., & Fukuda, T. (2022) · Hematological Oncology · doi:10.1002/hon.3115 · Cited by 17
Successful treatment with brentuximab vedotin for relapsed and refractory adult T cell leukemia
Oka, S., Ōno, K., & Nohgawa, M. (2020) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000895 · Cited by 17
Diagnosis and management of adult T-cell leukemia/lymphoma
Ishitsuka, K. (2021) · Seminars in Hematology · doi:10.1053/j.seminhematol.2021.02.005 · Cited by 17
Recent advances in T-cell lymphoid neoplasms
Bigas, A., Rodríguez‐Sevilla, J. J., Espinosa, L., & Gallardo, F. (2021) · Experimental Hematology · doi:10.1016/j.exphem.2021.12.191 · Cited by 17
Koseki, A., Araya, N., Yamagishi, M., Yamauchi, J., Yagishita, N., Takao, N., Takahashi, K., Kunitomo, Y., Honma, D., Araki, K., et al. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1175762 · Cited by 16
Oka, T., Matsuoka, K., & Utsunomiya, A. (2020) · Cancers · doi:10.3390/cancers12020335 · Cited by 16
Interferon regulatory factor 4 as a therapeutic target in adult T-cell leukemia lymphoma
Rauch, D. A., Olson, S. L., Harding, J. C., Sundaramoorthi, H., Kim, Y., Zhou, T., MacLeod, A. R., Challen, G. A., & Ratner, L. (2020) · Retrovirology · doi:10.1186/s12977-020-00535-z · Cited by 17
Clinicopathological significance of CD28 overexpression in adult T‐cell leukemia/lymphoma
Sakamoto, Y., Ishida, T., Masaki, A., Takeshita, M., Iwasaki, H., Yonekura, K., Tashiro, Y., Ito, A., Kusumoto, S., Iida, S., et al. (2021) · Cancer Science · doi:10.1111/cas.15191 · Cited by 17
Self-citationUpdates in the Treatment of Peripheral T-Cell Lymphomas
Saleh, K., Michot, J., & Ribrag, V. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s262344 · Cited by 15
Clinical factors to predict outcome following mogamulizumab in adult T-cell leukemia-lymphoma
Nakashima, J., Imaizumi, Y., Taniguchi, H., Ando, K., Iwanaga, M., Itonaga, H., Sato, S., Sawayama, Y., Hata, T., Yoshida, S., et al. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2509-0 · Cited by 15
Self-citationAdvances in the treatment of HTLV-1-associated adult T-cell leukemia lymphoma
Phillips, A. A. (2022) · Current Opinion in Virology · doi:10.1016/j.coviro.2022.101289 · Cited by 14
Yoshida‐Sakai, N., Watanabe, T., Yamamoto, Y., Ureshino, H., Kamachi, K., Kurahashi, Y., Fukuda‐Kurahashi, Y., & Kimura, S. H. (2021) · International Journal of Cancer · doi:10.1002/ijc.33901 · Cited by 14
Oka, S., Ōno, K., & Nohgawa, M. (2019) · Leukemia Research Reports · doi:10.1016/j.lrr.2019.04.001 · Cited by 14
Treatment of Adult T-Cell Leukemia/Lymphoma: Established Paradigms and Emerging Directions
Stuver, R. N., Horwitz, S. M., & Epstein-Peterson, Z. D. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01111-1 · Cited by 13
Shichijo, T., & Yasunaga, J. (2025) · Leukemia Research · doi:10.1016/j.leukres.2025.107680 · Cited by 13
Fujii, K., Sakamoto, Y., Masaki, A., Murase, T., Tashiro, Y., Yonekura, K., Utsunomiya, A., Ito, A., Kusumoto, S., Iida, S., et al. (2020) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.180 · Cited by 13
Self-citationSystematic review of survival outcomes for relapsed or refractory adult T‐cell leukemia‐lymphoma
Nosaka, K., Crawford, B., Yi, J., Kuan, W. Y., Matsumoto, T., & Takahashi, T. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13728 · Cited by 13
Self-citationJo, T., Matsuzaka, K., Shioya, H., TOMINAGA, H., SAKAI, T., Kaneko, Y., Hayashi, S., MATSUO, M., Taguchi, J., Abe, K., et al. (2020) · Anticancer Research · doi:10.21873/anticanres.14527 · Cited by 13
Self-citationNew treatments for adult T-cell leukemia/lymphoma
Epstein-Peterson, Z. D., Gurumurthi, A., & Horwitz, S. M. (2025) · Leukemia Research · doi:10.1016/j.leukres.2025.107642 · Cited by 11
Clinical Applications of Genomic Alterations in ATLL: Predictive Markers and Therapeutic Targets
Yoshida, N., Miyoshi, H., & Ohshima, K. (2021) · Cancers · doi:10.3390/cancers13081801 · Cited by 10
Sakamoto, H., Ando, K., Imaizumi, Y., Mishima, H., Kinoshita, A., Kobayashi, Y., Kitanosono, H., Kato, T., Sawayama, Y., Sato, S., et al. (2022) · Cancer Science · doi:10.1111/cas.15550 · Cited by 10
Self-citationPise-Masison, C. A., & Franchini, G. (2022) · Viruses · doi:10.3390/v14102084 · Cited by 11
Ikebe, E., Matsuoka, S., Tezuka, K., Kuramitsu, M., Okuma, K., Nakashima, M., Kobayashi, S., Makiyama, J., Yamagishi, M., Oyadomari, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001139 · Cited by 10
Fuji, S., Kida, S., Nakata, K., Morishima, T., Miyashiro, I., & Ishikawa, J. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04308-8 · Cited by 9
Makiyama, J., Ishitsuka, K., Munakata, W., Maruyama, D., & Nagai, H. (2023) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyad108 · Cited by 9
The small molecule STF-62247 induces apoptotic and autophagic cell death in leukemic cells
Kozako, T., Sato, K., Uchida, Y., Kato, N., Aikawa, A., Ogata, K., Kamimura, H., Uemura, H., Yoshimitsu, M., Ishitsuka, K., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25291 · Cited by 9
Self-citationAdult T-Cell Leukemia-Lymphoma
Munakata, W., & Tobinai, K. (2018) · Cancer treatment and research · doi:10.1007/978-3-319-99716-2_7 · Cited by 9
Self-citationGutowska, A., McKinnon, K. M., Sarkis, S., Doster, M. N., Bissa, M., Moles, R., Stamos, J. D., Rahman, M. A., Washington‐Parks, R., Davis, D. A., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.897264 · Cited by 9
Jo, T., Noguchi, K., Sakai, T., Kubota‐Koketsu, R., Irie, S., Matsuo, M., Taguchi, J., Abe, K., & Shigematsu, K. (2022) · Cancer Medicine · doi:10.1002/cam4.4689 · Cited by 8
Self-citationChemotherapy and allo-HSCT for young patients with aggressive ATL
Fuji, S. (2024) · Leukemia Research · doi:10.1016/j.leukres.2024.107596 · Cited by 8
Durer, C., & Babiker, H. M. (2020) · StatPearls · Cited by 8
Kondo, N., Nagano, Y., Hasegawa, A., Ishizawa, M., Katagiri, K., Yoneda, T., Masuda, T., & Kannagi, M. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.08.051 · Cited by 8
Emerging therapeutic strategies for mature T-cell and natural killer-cell lymphomas
Tse, E., Querfeld, C., Ishitsuka, K., & Kwong, Y. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00228-5 · Cited by 7
Suzuki, S., Kofune, H., Uozumi, K., Yoshimitsu, M., Arima, N., Ishitsuka, K., Ueno, S., & Kosai, K.-I. (2019) · BMC Cancer · doi:10.1186/s12885-019-5730-1 · Cited by 7
Self-citationEPOCH regimen as salvage therapy for adult T-cell leukemia–lymphoma
Toriyama, E., Imaizumi, Y., Taniguchi, H., Taguchi, J., Nakashima, J., Itonaga, H., Sato, S., Ando, K., Sawayama, Y., Hata, T., et al. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2455-x · Cited by 7
Self-citationTherapeutic advances for the management of adult T cell leukemia: Where do we stand?
Hajj, H. E., Hermine, O., & Bazarbachi, A. A. (2024) · Leukemia Research · doi:10.1016/j.leukres.2024.107598 · Cited by 6
Itonaga, H., Fukushima, T., Kato, K., Nakano, N., Kato, T., Tanaka, T., Eto, T., Mori, Y., Kawakita, T., Uchida, N., et al. (2024) · Hematological Oncology · doi:10.1002/hon.3315 · Cited by 6
Self-citationValente, M., Sanches, J. A., Nukui, Y., Cury‐Martins, J., Souza, B. C., Pereira, J. C., & Miyashiro, D. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1505865 · Cited by 7
Ando, T., Kojima, K., Sano, H., Kidoguchi, K., Kusaba, K., Yoshimura, M., Yokoo, M., Kubota, Y., Nakamura, H., Takase, Y., et al. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1427859 · Cited by 6
Teshigawara, K., Nagai, S., Bai, G., Okubo, Y., Yasutan, H. C., & Hattori, T. (2018) · Reports — Medical Cases Images and Videos · doi:10.3390/reports1020013 · Cited by 6
A Practical Guide to the Diagnosis, Evaluation, and Treatment of Cutaneous T-Cell Lymphoma
Shimshak, S. J. E., Sokumbi, O., Isaq, N. A., Goyal, A., & Comfere, N. I. (2022) · Dermatologic Clinics · doi:10.1016/j.det.2022.07.019 · Cited by 6
R-loops in normal and malignant hematopoiesis
Hirayama, M., Shinriki, S., & Matsui, H. (2023) · Frontiers in Hematology · doi:10.3389/frhem.2023.1297657 · Cited by 5
Stem cell therapy for HTLV-1 induced adult T-cell leukemia/lymphoma (ATLL): A comprehensive review
Gholamzad, A., Khakpour, N., Gholamzad, M., Sarvandani, M. R. R., Khosroshahi, E. M., Asadi, S., Rashidi, M., & Hashemi, M. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155172 · Cited by 5
Tamaki, K., Morishima, S., Nomura, S., Nishi, Y., Nakachi, S., Kitamura, S., Uchibori, S., Tomori, S., Hanashiro, T., Shimabukuro, N., et al. (2018) · Cancer Science · doi:10.1111/cas.13641 · Cited by 5
Self-citationNationwide Hospital-Based Survey of Adult T-Cell Leukemia/Lymphoma in Japan
Kato, T., Imaizumi, Y., & Miyazaki, Y. (2022) · Viruses · doi:10.3390/v14040791 · Cited by 5
Self-citationFukushima, T., Itonaga, H., Sakamoto, H., Takeda, W., Tokunaga, M., Kato, T., Kuriyama, T., Kawakita, T., Fujioka, M., Miyazaki, Y., et al. (2025) · Transplant Infectious Disease · doi:10.1111/tid.70070 · Cited by 4
Self-citationLi, K., Shuping, S., Chang, S., Yiyue, C., Qinyu, X., Zhang, T., & Wu, B. (2023) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2389 · Cited by 4
Metadata
- Authors
- Ishida, T., Fujiwara, H., Nosaka, K., Taira, N., Abe, Y., Imaizumi, Y., Moriuchi, Y., Jo, T., Ishizawa, K., Tobinai, K., Tsukasaki, K., Ito, S., Yoshimitsu, M., Otsuka, M., Ogura, M., Midorikawa, S., Ruiz, W., & Ohtsu, T.
- Affiliations
- Nagoya City University (JP)
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2016-12-01
- Volume
- 34
- Issue
- 34
- Pages
- 4086-4093
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2519997684
- Cited by
- 152
- References
- 44
- Citations by year
- 2026: 7 · 2025: 16 · 2024: 9 · 2023: 13 · 2022: 13 · 2021: 24 · 2020: 21 · 2019: 16 · 2018: 18 · 2017: 15
- FWCI
- 9.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (16H04713, 15K09506)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- lenalidomide, adult T-cell leukemia/lymphoma, monotherapy, overall response rate, progression-free survival, neutropenia, adverse events, T-cell neoplasms
- MeSH terms
- Lenalidomide, Administration, Oral, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Prognosis, Recurrence, Remission Induction, Thalidomide, Leukemia-Lymphoma, Adult T-Cell, Survival Rate, Treatment Outcome, Disease Progression, Angiogenesis Inhibitors, Endpoint Determination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
